Front Row Advisors’s Cardiff Oncology CRDF Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-1
| Closed | -$3 | – | 558 |
|
|
2025
Q4 | $3 | Hold |
1
| – | – | ﹤0.01% | 553 |
|
|
2025
Q3 | $2 | Hold |
1
| – | – | ﹤0.01% | 552 |
|
|
2025
Q2 | $3 | Sell |
1
-1
| -50% | -$3 | ﹤0.01% | 535 |
|
|
2025
Q1 | $6 | Hold |
2
| – | – | ﹤0.01% | 509 |
|
|
2024
Q4 | $9 | Buy |
+2
| New | +$6 | ﹤0.01% | 499 |
|
|
2024
Q3 | – | Sell |
-2
| Closed | -$4 | – | 582 |
|
|
2024
Q2 | $4 | Hold |
2
| – | – | ﹤0.01% | 940 |
|
|
2024
Q1 | $11 | Hold |
2
| – | – | ﹤0.01% | 925 |
|
|
2023
Q4 | $3 | Hold |
2
| – | – | ﹤0.01% | 472 |
|
|
2023
Q3 | $3 | Hold |
2
| – | – | ﹤0.01% | 918 |
|
|
2023
Q2 | $0 | Hold |
2
| – | – | ﹤0.01% | 898 |
|
|
2023
Q1 | $0 | Buy |
+2
| New | +$3 | ﹤0.01% | 914 |
|
|
2022
Q2 | – | Sell |
-2
| Closed | – | – | 927 |
|
|
2022
Q1 | $0 | Hold |
2
| – | – | ﹤0.01% | 933 |
|
|
2021
Q4 | $0 | Hold |
2
| – | – | ﹤0.01% | 943 |
|
|
2021
Q3 | $0 | Hold |
2
| – | – | ﹤0.01% | 942 |
|
|
2021
Q2 | $0 | Buy |
+2
| New | +$17 | ﹤0.01% | 951 |
|
|
2021
Q1 | – | Sell |
-2
| Closed | – | – | 958 |
|
|
2020
Q4 | $0 | Hold |
2
| – | – | ﹤0.01% | 913 |
|
|
2020
Q3 | $0 | Hold |
2
| – | – | ﹤0.01% | 927 |
|
|
2020
Q2 | $0 | Hold |
2
| – | – | ﹤0.01% | 995 |
|
|
2020
Q1 | $0 | Hold |
2
| – | – | ﹤0.01% | 988 |
|
|
2019
Q4 | $0 | Hold |
2
| – | – | ﹤0.01% | 917 |
|
|
2019
Q3 | $0 | Hold |
2
| – | – | ﹤0.01% | 949 |
|
|
2019
Q2 | $0 | Hold |
2
| – | – | ﹤0.01% | 1040 |
|
|
2019
Q1 | $0 | Buy |
+2
| New | +$7 | ﹤0.01% | 1067 |
|
Other funds holding CRDF
VCM
LCM
P
ACA
FLPIM